{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:07:40Z","timestamp":1794935260047,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sichuan Provincial Science and Technology Projects","award":["2017SZ0069"],"award-info":[{"award-number":["2017SZ0069"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Combined hepatocellular-cholangiocarcinoma (CHCC) is a rare type of primary liver cancer (PLC). The aim of this study was to investigate the disease characteristics in CHCC patients and compare them with those in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).<\/jats:p>\n                    <jats:p>The perioperative and follow-up data of CHCC patients (n\u200a=\u200a15), HCC patients (n\u200a=\u200a577), and ICC patients (n\u200a=\u200a61) were retrospectively analyzed, and the clinicopathological characteristics were compared among these 3 groups.<\/jats:p>\n                    <jats:p>\n                      In the CHCC group, the serum level of AFP was significantly higher than that of the ICC group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.002), and the CA19-9 level was higher than that of the HCC group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.011). The positive rates of CK7 and CK19 expression were higher in CHCC group than in HCC group (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001), while the positive rates of Glypican\u20133 and Hepatocyte expression were higher in CHCC group than in ICC group (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001). Meanwhile, the CHCC patients were likely to have undergone more MJH\/LT than the HCC patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.037) and the ICC patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.011). Macrovascular invasion and lymph node metastasis in the CHCC group were significantly higher but satellite lesions were similar, compared to the HCC group. Both the 1-year disease-free survival (DFS) and the 1-year overall survival (OS) for the CHCC patients were worse than those for the HCC patients. AFP\u200a\u2265\u200a400\u200ang\/ml, tumor size \u22655\u200acm, tumor number \u22652, macro- and microvascular invasion, distant metastasis and positive margin were risk factors for both DFS and OS for the PLC patients. Multivariate analysis also confirmed that ICC and lymph node metastasis were risk factors for DFS and MJH\/LT was risk factor for OS.\n                    <\/jats:p>\n                    <jats:p>CHCC patients appear to have intermediate clinical characteristics in comparison with the HCC and ICC patients, and the 1-year DFS and OS for the CHCC patients was worse than the HCC patients, but similar to the ICC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000017102","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T23:51:10Z","timestamp":1569887470000},"page":"e17102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Combined hepatocellular-cholangiocarcinoma"],"prefix":"10.1097","volume":"98","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Hospital Affiliated to University of Electronic Science and Technology of China & Sichuan Provincial People's Hospital, Chengdu, Sichuan, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,9]]},"reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1155\/2010\/917356","article-title":"Outcome of combined hepatocellular and cholangiocarcinoma of the liver","volume":"2010","author":"Wang","year":"2010","journal-title":"J Oncol"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/hep.25874","article-title":"Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma","volume":"56","author":"Cai","year":"2012","journal-title":"Hepatology (Baltimore, Md )"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3346\/jkms.2011.26.8.1023","article-title":"Clinicopathologic study on combined hepatocellular carcinoma and cholangiocarcinoma: with emphasis on the intermediate cell morphology","volume":"26","author":"Park","year":"2011","journal-title":"J Korean Med Sci"},{"key":"R4-20260519","first-page":"647","article-title":"Combined liver cell and bile duct carcinoma","volume":"25","author":"Allen","year":"1949","journal-title":"Am J Pathol"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1097-0142(19850101)55:1<124::AID-CNCR2820550120>3.0.CO;2-Z","article-title":"Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study","volume":"55","author":"Goodman","year":"1985","journal-title":"Cancer"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.3748\/wjg.v12.i39.6261","article-title":"Hepatic progenitor cells in human liver tumor development","volume":"12","author":"Libbrecht","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1665-2681(19)30859-2","article-title":"Combined hepatocellular-cholangiocarcinoma (cHCC-CC): a distinct entity","volume":"13","author":"O\u2019Connor","year":"2014","journal-title":"Ann Hepatol"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MCG.0b013e3181ce5dfa","article-title":"Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma","volume":"45","author":"Lee","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/cncr.10392","article-title":"Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors","volume":"94","author":"Jarnagin","year":"2002","journal-title":"Cancer"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/lt.23897","article-title":"Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor","volume":"20","author":"Garancini","year":"2014","journal-title":"Liver Transpl"},{"key":"R12-20260519","first-page":"1227","article-title":"Indication of liver transplantation for hepatocellular carcinoma: Shanghai Fudan Criteria","volume":"86","author":"Fan","year":"2006","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/MEG.0000000000000454","article-title":"Ki67 as a prognostic factor for long-term outcome following surgery in gastrointestinal stromal tumors","volume":"27","author":"Turkel Kucukmetin","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jgh.12692","article-title":"Epithelial cell adhesion molecule-positive human hepatic neoplastic cells: development of combined hepatocellular-cholangiocarcinoma in mice","volume":"30","author":"Ogasawara","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"R15-20260519","doi-asserted-by":"crossref","first-page":"12615","DOI":"10.3748\/wjg.v20.i35.12615","article-title":"Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study","volume":"20","author":"Zhou","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.3748\/wjg.v22.i18.4459","article-title":"Combined hepatocellular cholangiocarcinoma: controversies to be addressed","volume":"22","author":"Wang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3349\/ymj.2011.52.5.753","article-title":"Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma: a single center study in Korea","volume":"52","author":"Park","year":"2011","journal-title":"Yonsei Med J"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1440-1746.2012.07289.x","article-title":"Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers","volume":"28","author":"Lee","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1499-3872(14)60275-7","article-title":"Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery","volume":"13","author":"Lee","year":"2014","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/jmri.23754","article-title":"Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients","volume":"36","author":"de Campos","year":"2012","journal-title":"J Magn Reson Imaging"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2214\/AJR.12.9488","article-title":"Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI","volume":"201","author":"Fowler","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1872-034X.2012.01107.x","article-title":"Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma","volume":"43","author":"Ijichi","year":"2013","journal-title":"Hepatol Res"},{"key":"R23-20260519","first-page":"30194","article-title":"Liver transplantation and combined hepatocellular-cholangiocarcinoma: feasibility and outcomes","volume":"6","author":"Magistri","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R24-20260519","doi-asserted-by":"crossref","first-page":"66","DOI":"10.21037\/cco.2016.10.02","article-title":"Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma","volume":"5","author":"Connell","year":"2016","journal-title":"Chinese Clin Oncol"},{"key":"R25-20260519","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1245\/s10434-011-2150-0","article-title":"Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor","volume":"19","author":"Ariizumi","year":"2012","journal-title":"Ann Surg Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:00:23Z","timestamp":1779206423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017102"}},"subtitle":["An analysis of clinicopathological characteristics after surgery"],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":24,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017102","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"2019-03-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}